NasdaqCM - Nasdaq Real Time Price USD

Citius Oncology, Inc. (CTOR)

0.9162

+0.0231

+(2.59%)

At close: May 13 at 4:00:00 PM EDT

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Name	Title	Pay	Exercised	Year Born
Mr. Leonard L. Mazur	Chairman, CEO & President	166.25k	--	1945
Mr. Myron Z. Holubiak	Executive Vice Chairman & Secretary	450k	--	1947
Dr. Myron S. Czuczman M.D.	Chief Medical Officer	225k	--	1960
Mr. Jaime Bartushak	CFO & Treasurer	--	--	1968

420 Lexington Avenue

Suite 2446

New York, NY 10170

United States

347-627-0058

Sector:: Healthcare
Industry:

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

Citius Oncology, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events Information Not Available

April 25, 2025 at 12:00 AM UTC